Rynex Pse NDC 0485-0206

NDC codes

FDA NDC Directory

Product NDC (as listed)0485-0206Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00485-0206Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0485-0206-16	00485020616	473 mL in 1 BOTTLE, PLASTIC (0485-0206-16)Marketed from Mar 7, 2011

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rynex Pse
Generic name (nonproprietary): brompheniramine maleate and pseudoephedrine hydrochloride
Active ingredients: Brompheniramine maleate — 1 mg/5mLPseudoephedrine hydrochloride — 15 mg/5mL
Dosage form: Liquid
Route: Oral
Labeler: EDWARDS PHARMACEUTICALS, INC.
Product type: Over-the-counter drug
Marketing category: Unapproved drug (other)
Marketing start: Mar 7, 2011
Listing expires: Dec 31, 2027
Other FDA classes: Adrenergic alpha-Agonists (Mechanism)
Identifiers: Product ID 0485-0206_4c48242c-1746-1a49-e063-6294a90ac81dSPL ID 4c48242c-1746-1a49-e063-6294a90ac81dSPL set ID 2f2d9b5a-f66b-4928-8d43-402ef9efcfdfRxCUI 1098498UNII IXA7C9ZN03, 6V9V2RYJ8N
Pharmacologic class: alpha-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400485020616 followed by a unit qualifier and the quantity

Package 00485-0206-16. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 5, 2026.

Indications (excerpt from the label)

Uses temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other respiratory allergies: runny nose sneezing itching of the nose or throat itchy, watery eyes nasal congestion 'reduces swelling of nasal passages

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)